The therapies available for the effective treatment of hypertension or end-organ complications of hypertension continue to experience almost a geometric growth in their numbers. Such a proliferation of therapies creates a conundrum of sorts for the treating physician. The physician is called upon to position a new drug class in comparison to traditional therapies, oftentimes without adequate information to reach such therapeutic distinctions. In addition, as new members of a drug class inevitably become available, it is incumbent upon the physician to determine the relevance of supposed pharmacokinetic and pharmacodynamic differences. This is the case with the angiotensin-receptor antagonists (AT1-RAs). Seven such compounds are currently marketed in the United States and considerable controversy exists as to the significance of differences—both pharmacokinetic and pharmacodynamic—among individual class members. This is very much analogous to the present situation with angiotensin-converting enzyme (ACE) inhibitors, among which compounds 10 are available in the United States.